ClinicalTrials.gg
Active, not recruitingNCT06203054Updated Oct 29, 2026Results posted

CLIP-IT Post-Market Study

An interventional study of Penditure™ Left Atrial Appendage (LAA) Exclusion System in Left Atrial Appendage Exclusion, sponsored by Medtronic Cardiac Surgery. Active, not recruiting at 15 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Not applicable, Interventional, and Treatment

How we know

Updated Oct 29, 2026Results postedPrimary outcomes revisedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
198
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to collect post-market clinical evidence on performance and clinical outcomes of the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.

Read the detailed description

Multi center, single-arm, nonrandomized, interventional, unblinded, post-market study. Up to 150 subjects will be enrolled and implanted with the Penditure™ Left Atrial Appendage (LAA) Exclusion Clip at up to 25 sites in the United States.

Subjects will be followed at 30 days, 3 months, 12-months and annually for 36-months.

02

Conditions studied

  • Left Atrial Appendage Exclusion
03

In context

Lead sponsor

Medtronic Cardiac Surgery is the lead sponsor of 9 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is indicated to be treated with the Penditure™ left atrial appendage (LAA) Exclusion System
  • Greater than or equal to 18 years of age
  • The subject is willing and able to provide written and comply with study visit requirements

Exclusion criteria

Exclusion Criteria:

  • Prior left atrial appendage (LAA) isolation attempt(s)
  • Need for emergent cardiac surgery
  • Subject is for multi-detector computed tomography (MDCT) and/or transesophageal echocardiogram (TEE)
  • of less than 12 months
  • History of cardiac surgery
  • Pericarditis
  • Presence of thrombus in the left atrium or left atrial appendage (LAA), prior to or during the procedure
  • Patients requiring a heart transplant, insertion of a ventricular assist device or total artificial heart, and/or ascending aortic aneurysm or dissection repair requiring circulatory arrest
  • Society of Thoracic Surgeons Predicted Risk of Mortality (STS-PROM) score greater than 4 or subject deemed to be high or extreme risk per surgeon assessment
  • less than 30%
  • Chronic Kidney Disease Stage IV or V (estimated (eGFR) \<30 ml/min)
  • (NYHA) Class IV heart failure symptoms
  • Patient has a documented history of substance (drug or alcohol) abuse
  • Known allergy to device components (Nickel and/or Titanium)
  • In the opinion of the investigator, the subject is not a suitable candidate for LAA isolation due to risks outweighing potential benefits including, complexity of planned concomitant procedures, or other pre-existing medical conditions
  • Currently participating in an drug or another device trial or study (excluding registries)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
198 participants (actual)

Study arms

  • Experimental
    Penditure™ Left Atrial Appendage (LAA) Exclusion System

    Penditure™ Left Atrial Appendage (LAA) Exclusion System

    Device: Penditure™ Left Atrial Appendage (LAA) Exclusion System

Interventions

  • DevicePenditure™ Left Atrial Appendage (LAA) Exclusion System

    Exclusion of the left atrial appendage using the Penditure™ Left Atrial Appendage (LAA) Exclusion System in subjects undergoing concomitant cardiac surgery.

06

What researchers measure

Primary outcomes

  1. Rate of Successful Exclusion of the Left Atrial Appendage (LAA) From the Heart

    The primary efficacy endpoint is the rate of successful exclusion of the left atrial appendage (LAA) from the heart defined as the absence of residual communication (≤ 3 mm residual contrast communication) between the left atrium (LA) and the left atrial appendage (LAA). For those successfully placed devices, exclusion will be confirmed at 3 months as demonstrated by multi-detector computed tomography (MDCT) scan.

    Time frame: 3 months post procedure

  2. Rate of Device-related Serious Adverse Cardiac Events

    The primary safety endpoint is the composite rate of device-related serious adverse cardiac events at 30-days post-procedure.

    Time frame: 30 days post procedure

Secondary outcomes

  1. Rate of Successful Placement of the Penditure™ Left Atrial Appendage (LAA) Exclusion System

    The secondary efficacy endpoint is defined as the rate of successful placement of the Penditure™ LAA Exclusion System defined as \< 10 mm of residual stump proximal to the clip at the time of the procedure (measured by intraoperative TEE with doppler) without tissue damage requiring intervention.

    Time frame: At the time of procedure

  2. Rate of Device-related Serious Adverse Cardiac Events

    The secondary safety endpoint is defined as the composite device-related serious adverse cardiac event rate at 12-months and annually through 36 months.

    Time frame: At 1 year, 2 year, and 3 years post procedure

07

Results

Posted Oct 29, 2026

Participant flow

Enrollment was between February 26, 2024, and March 26, 2025. Enrollments occurred at the investigational sites that performed the Penditure implant.

Participant flow — Overall Study
MilestonePenditure™ Left Atrial Appendage (LAA) Exclusion System
Started198
Completed150
Not completed48
Withdrew: Withdrawal by subject5
Withdrew: Death1
Withdrew: Physician decision31
Withdrew: Enrollment cap = 7, exclusion met after enrollment = 411

Outcome measures

PrimaryRate of Successful Exclusion of the Left Atrial Appendage (LAA) From the Heart

The primary efficacy endpoint is the rate of successful exclusion of the left atrial appendage (LAA) from the heart defined as the absence of residual communication (≤ 3 mm residual contrast communication) between the left atrium (LA) and the left atrial appendage (LAA). For those successfully placed devices, exclusion will be confirmed at 3 months as demonstrated by multi-detector computed tomography (MDCT) scan.

Time frame:
3 months post procedure
Reported as:
Count of participants · Participants
Rate of Successful Exclusion of the Left Atrial Appendage (LAA) From the Heart
ParticipantsPenditure™ Left Atrial Appendage (LAA) Exclusion System
Rate of Successful Exclusion of the Left Atrial Appendage (LAA) From the Heart135
Statistical analysis
  • Penditure™ Left Atrial Appendage (LAA) Exclusion System · Other: 100
PrimaryRate of Device-related Serious Adverse Cardiac Events

The primary safety endpoint is the composite rate of device-related serious adverse cardiac events at 30-days post-procedure.

Time frame:
30 days post procedure
Reported as:
Count of participants · Participants
Rate of Device-related Serious Adverse Cardiac Events
ParticipantsPenditure™ Left Atrial Appendage (LAA) Exclusion System
Rate of Device-related Serious Adverse Cardiac Events0
Statistical analysis
  • Penditure™ Left Atrial Appendage (LAA) Exclusion System · Clopper-pearson exact method: 0 · 95% CI 0 to 2.04
SecondaryRate of Successful Placement of the Penditure™ Left Atrial Appendage (LAA) Exclusion System

The secondary efficacy endpoint is defined as the rate of successful placement of the Penditure™ LAA Exclusion System defined as \< 10 mm of residual stump proximal to the clip at the time of the procedure (measured by intraoperative TEE with doppler) without tissue damage requiring intervention.

Time frame:
At the time of procedure
Reported as:
Count of participants · Participants
Rate of Successful Placement of the Penditure™ Left Atrial Appendage (LAA) Exclusion System
ParticipantsPenditure™ Left Atrial Appendage (LAA) Exclusion System
Rate of Successful Placement of the Penditure™ Left Atrial Appendage (LAA) Exclusion System145
Statistical analysis
  • Penditure™ Left Atrial Appendage (LAA) Exclusion System · Clopper-pearson exact method: 98.6 · 95% CI 95.17 to 99.83
SecondaryRate of Device-related Serious Adverse Cardiac Events

The secondary safety endpoint is defined as the composite device-related serious adverse cardiac event rate at 12-months and annually through 36 months.

Time frame:
At 1 year, 2 year, and 3 years post procedure

Results for this outcome have not been posted.

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Penditure™ Left Atrial Appendage (LAA) Exclusion System5/150 (3.3%)59/150 (39.3%)—
Most frequent serious events
Showing 10 of 44
Most frequent serious events
EventPenditure™ Left Atrial Appendage (LAA) Exclusion System
Atrial fibrillationCardiac disorders28/150
Atrial flutterCardiac disorders4/150
Cardiogenic shockCardiac disorders4/150
Atrioventricular block completeCardiac disorders3/150
Cardiac tamponadeCardiac disorders3/150
Coronary artery diseaseCardiac disorders3/150
HaemorrhageVascular disorders3/150
Cardiac arrestCardiac disorders2/150
Cardiac failure congestiveCardiac disorders2/150
Ventricular dysfunctionCardiac disorders2/150

Baseline characteristics

Age, Continuous
Age, Continuous(years)Penditure™ Left Atrial Appendage (LAA) Exclusion System
Mean67.57 ± 9.86
Sex: Female, Male
Sex: Female, Male(Participants)Penditure™ Left Atrial Appendage (LAA) Exclusion System
Female38
Male112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Penditure™ Left Atrial Appendage (LAA) Exclusion System
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American6
White140
More than one race0
Unknown or Not Reported1
Region of Enrollment
Region of Enrollment(Participants)Penditure™ Left Atrial Appendage (LAA) Exclusion System
United States150
BMI
BMI(kg/m^2)Penditure™ Left Atrial Appendage (LAA) Exclusion System
Mean30.00 ± 5.91
STS Predicted Risk of Mortality (%)
STS Predicted Risk of Mortality (%)(Percent Predicted Risk of Mortality)Penditure™ Left Atrial Appendage (LAA) Exclusion System
Mean1.68 ± 1.37
STS not applicable, surgeon assessed risk level
STS not applicable, surgeon assessed risk level(Participants)Penditure™ Left Atrial Appendage (LAA) Exclusion System
Low Risk15
Intermediate Risk5
High Risk/Extreme Risk0
Ejection Fraction (%)
Ejection Fraction (%)(Percent of ejected blood from ventricle)Penditure™ Left Atrial Appendage (LAA) Exclusion System
Mean57.46 ± 8.74

3 further baseline measures are reported on the registry.

08

Study locations

15 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2024 to primary completion in Aug 2025, 18 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2024
First posted
Jan 12, 2024
StartActual
Feb 26, 2024
Primary completionActual
Aug 26, 2025
CompletionEst.
Feb 2029
Results first posted
Oct 29, 2026
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 29, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedRate of successful exclusionSuccessful Exclusion of the left atrial appendageLeft Atrial Appendage (LAA) fromFrom the heartHeartTime frame: 3 months post procedure
  • EditedRate of device Device-related adverse eventsSerious Adverse Cardiac EventsTime frame: 30 days post procedure
Oct 29, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedRate of successful placementSuccessful Placement of the Penditure™ left atrial appendageLeft Atrial Appendage (LAA) Exclusion SystemTime frame: At the time of procedure
  • EditedRate of device Device-related adverse eventsSerious Adverse Cardiac EventsTime frame: At 1 year, 2 year, and 3 years post procedure
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Results posted
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedRate of successful exclusionSuccessful Exclusion of the left atrial appendageLeft Atrial Appendage (LAA) fromFrom the heartHeartTime frame: 3 months post procedure
    • EditedRate of device Device-related adverse eventsSerious Adverse Cardiac EventsTime frame: 30 days post procedure
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedRate of successful placementSuccessful Placement of the Penditure™ left atrial appendageLeft Atrial Appendage (LAA) Exclusion SystemTime frame: At the time of procedure
    • EditedRate of device Device-related adverse eventsSerious Adverse Cardiac EventsTime frame: At 1 year, 2 year, and 3 years post procedure
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06203054
Responsible party
Sponsor
First posted
Jan 12, 2024
Start date
Feb 26, 2024
Primary completion
Aug 26, 2025
Completion
Feb 2029 (estimated)
Results posted
Oct 29, 2026
Last update
Oct 29, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion